Carbetocin to prevent heavy bleeding after twin birth
Official title: Carbetocin Administration for the Prevention of Postpartum Hemorrhage in Twin Deliveries: A Randomized Controlled Trial
Run by Sheba Medical Center · NCT07401524 · Data updated 2026-11-12
This trial tests whether a single dose of carbetocin given after the second twin is born reduces heavy bleeding compared with standard oxytocin in people delivering twins.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 120 (estimated) |
| Sponsor | Sheba Medical Center Government |
| Locations | 1 site (Ramat Gan) |
| Status | Recruiting |
| Started | May 5, 2026 |
| Main results expected | March 1, 2028 |
| Study ends | December 1, 2028 |
| Registry record updated | May 8, 2026 |
| Trial ID | NCT07401524 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pregnant individuals aged 18 or older with a twin pregnancy at or beyond 23 weeks who plan to deliver at Sheba Medical Center and have no contraindication to carbetocin or oxytocin.
✕Probably not a fit
Patients with known hypersensitivity to carbetocin/oxytocin, placenta accreta spectrum, bleeding disorders, hyponatremia that precludes oxytocin, intrauterine fetal death, higher-order multiples, or those planning delivery outside the participating hospital are unlikely to qualify or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, randomized phase 4 trial at Sheba Medical Center will assign pregnant people with twin pregnancies (≥23 weeks and age ≥18) in a 1:1 ratio to receive either prophylactic carbetocin or standard oxytocin after the second twin is delivered. Blood loss will be quantified by the drop in hemoglobin from before delivery to the day after delivery, and investigators will record safety outcomes such as need for additional uterotonics, transfusion, and adverse events. The trial includes both vaginal and cesarean twin deliveries and excludes higher-order multiples, placenta accreta, bleeding disorders, and intrauterine fetal death. The primary aim is to see if carbetocin lowers postpartum blood loss and is safe and practical compared with oxytocin.
Why it matters
Potential benefit: If successful, carbetocin could reduce postpartum blood loss in twin deliveries and lower rates of anemia, transfusion, and related complications.
How similar studies have gone: Previous randomized trials and meta-analyses have shown carbetocin reduces the need for additional uterotonics and transfusion, primarily after cesarean delivery, but randomized data specifically in twin pregnancies are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant individuals aged ≥18 years * Twin pregnancies * Gestational age ≥23 weeks Exclusion Criteria: * Known hypersensitivity or contraindication to carbetocin * Higher-order multiple gestation (triplets or more) * Maternal age \<18 years * Known placenta accreta spectrum * Known bleeding disorder * Intrauterine fetal death of one or more fetuses * Hyponatremia precluding oxytocin use * Planned delivery at a non-participating hospital
Where it's running
-
Sheba Medical Center
Ramat Gan, Israel Recruiting
Study contacts
- Study coordinator: Avihu Krieger, MD
- Email: avihuey@gmail.com
- Phone: +972547421909
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term outcomes after vacuum-induced tamponade for postpartum hemorrhage
This study will look at women who had postpartum hemorrhage treated with vacuum-induced tamponade at a Zurich hospital to see how they fared over time, including future pregnancies and fertility.
-
Calcium Gluconate After Birth to Reduce Blood Loss in Vaginal Delivery
This study tests whether giving calcium gluconate right after the baby is born can help reduce blood loss for people having a vaginal delivery.
-
Carbetocin Alone vs Carbetocin Plus Oxytocin After Elective Cesarean Delivery
This study tests whether giving carbetocin by itself after an elective cesarean is just as good as adding a supplemental oxytocin infusion.
-
Simulation-based postpartum hemorrhage training to boost anesthesiology team performance
Senior anesthesiology residents will try a high-fidelity simulation program for postpartum hemorrhage to see if it improves how their teams perform during obstetric emergencies.
-
Bone mineral density in late pregnancy: singleton versus twin gestations
This project tests whether women with twin pregnancies have different bone mineral density in the third trimester than women carrying one baby, using two questionnaires and REMS ultrasound densitometry.
-
Draining the umbilical cord after birth to lower postpartum bleeding
This trial tests whether draining blood from the cut umbilical cord right after birth lowers heavy bleeding after delivery in women having a term vaginal birth.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.